2.9100 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||2.9100 x 3100|
|Ask||3.0500 x 1800|
|Day's Range||2.7767 - 3.0900|
|52 Week Range||2.2000 - 7.5000|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2020 - May 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall favorable for Pacific Biosciences, but mixed in terms of its findings. The jury declined to find valid or infringed U.S. Patent No. 9,738,929, also asserted by Pacific Biosciences in the actions. “We are disappointed with today’s verdict, which appears to be internally inconsistent regarding the validity of our patents,” said Dr. Michael W. Hunkapiller, President and Chief Executive Officer of Pacific Biosciences.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors. As part of its annual review of the leadership structure of Pacific Biosciences, the Board of Directors decided to separate the Chairman and Chief Executive Officer positions in alignment with best practices. Mr. Henry will become Chairman of the Board, effective immediately and Dr. Michael Hunkapiller will continue to serve as President and Chief Executive of the Company, as well as an active member of the board.
The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of ecologically important organisms in the state of California through the EBP. The effort will be centered at the University of California, Davis.
There are now 34,822 confirmed cases of coronavirus worldwide and at least 724 people have died, according to the latest figures from the World Health Organization (WHO).
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020. Mr. Phillips has directed the development of PacBio’s technology since joining the company in 2005.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif., Feb. 06, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31,.
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Pacific Biosciences of California, Inc. (NASDAQ:PACB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February ...
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
(Bloomberg Opinion) -- When the world’s competition police reflect on big tech’s dealmaking over the past 15 years, you could forgive them for wondering what might have been. If Facebook Inc. hadn’t acquired WhatsApp or Instagram, or if Google hadn’t bought YouTube or DoubleClick, would there be stronger competition for the two Silicon Valley firms?It certainly seems that regulators, particularly in the U.K., are eager to avoid repeat scenarios where companies grab outsize control of an emerging market before it’s clear exactly how important or big that market may be. That’s why a 6.1 billion-pound ($8 billion) food delivery takeover may have broader implications for tech giants’ dealmaking-to-come.Britain’s Competition and Markets Authority is reviewing the Dutch firm Takeaway.com NV’s planned acquisition of Just Eat Plc, the U.K.’s online marketplace for restaurant delivery. It’s a remarkable step, given that Takeaway.com no longer has a British business, and so the two firms don’t currently compete, at least not in the U.K. The regulator, the CMA, is instead pondering hypotheticals. It’s deliberating whether, without a deal, Takeaway.com might still otherwise enter the market and add a healthy dose of competition.The move underscores a recent approach that could make it more difficult for tech giants to make acquisitions, even small ones. (Together, they’ve bought more than 250 companies in the last six years.) Companies might not obviously compete with the firm acquiring them, but the U.K. watchdog is increasingly taking into account the possibility they could become a competitor at some later stage. It seems to have listened to the findings of the government-commissioned review into digital competition last year by Jason Furman, previously economic adviser to former U.S. President Barack Obama, which recommended that the CMA should take “more frequent and firmer action to challenge mergers that could be detrimental to consumer welfare through reducing future levels of innovation and competition.”Across the Atlantic, DNA-sequencing firm Illumina Inc.’s scuppered $1.2 billion acquisition of smaller peer Pacific Biosciences of California Inc. also illustrates the challenge. Both firms are active in slightly different parts of the market, so do not directly compete: Illumina currently focuses on so-called short-read sequencing platforms, while PacBio’s expertise is in long-reads. Yet antitrust authorities in both the U.K. and U.S. pushed back against the deal because of concerns that Illumina would decide against developing its own long-read offering further down the line, according to Bloomberg Intelligence analyst Aitor Ortiz. The firms called the deal off earlier this month.It’s healthy that technology deals are likely to attract more scrutiny. Acquisitions sometimes look like a catch-and-kill strategy: buying a startup that could become a rival before it's able to do so without necessarily using it to augment the business directly. For example, back in 2017, Facebook bought the fast-growing teen app tbh, before shutting it down just eight months later, citing low usage.But doing so presents a potential challenge for the CMA: ensuring that the U.K. remains an attractive place to found technology firms. Venture capitalists and big companies themselves often argue that a lot of startups are founded with the intention of ultimately selling themselves to a larger rival. If that exit strategy disappears, runs the argument, then they might decide to set up shop elsewhere.So far, it’s too early to determine whether that argument has any merit. And analysts still expect the Takeaway.com-Just Eat deal to complete, albeit with a slight delay. But because the CMA has the authority to impose remedies without a court case, unlike the U.S.’s Federal Trade Commission, technology firms have good reason to be wary.To contact the author of this story: Alex Webb at email@example.comTo contact the editor responsible for this story: Melissa Pozsgay at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Alex Webb is a Bloomberg Opinion columnist covering Europe's technology, media and communications industries. He previously covered Apple and other technology companies for Bloomberg News in San Francisco.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
MENLO PARK, Calif., Jan. 21, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Fourth Quarter 2019 Financial.
Genetic sequencing giant Illumina Inc. has nixed its $1.2 billion acquisition attempt of Menlo Park's Pacific Biosciences amid intense regulator scrutiny. San Diego-based Illumina announced the all-cash deal to purchase its smaller competitor in 2018, but it has faced an uphill battle to convince regulators in the U.S. and Europe. In October, antitrust regulators in the UK put out a statement of concern about the proposed merger given Illumina's immense market power in the highly-concentrated DNA sequencing industry.
U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...